|

Alzheimer's Disease Clinical Trials in New Jersey

28 recruiting studies across 14 cities

All Trials in New Jersey

Phase
Trial Phase Location
Comparison of Two Group Wellness Interventions for Individuals With Neurologic Conditions and Their Support PersonsN/AEast Hanover
Ultralow Dose PET Imaging of 18F-Florbetapir, 18F-FlutemetamolPhase 2Englewood
Pulsed Electromagnetic Field Treatment In Patients With Alzheimer's DiseaseN/AHackensack
Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986368, for the Treatment of Agitation in Participants With Alzheimer's DiseasePhase 2Livingston
A Clinical Study of MK-2214 in People With Early Alzheimer's Disease (MK-2214-004)Phase 2Marlton
A Study of LY4006895 in Healthy Participants With Early Symptomatic Alzheimer's Disease (AD)Phase 1Marlton
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1)Phase 3Middletown
ALA-enriched Nutrition for Prevention of Cognitive Decline in APOE4 Older AdultsPhase 2New Brunswick
Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR VariantPhase 3New Brunswick
Clinical Study of SNK01 in Participants With Moderate Alzheimer's DiseasePhase 1/2Newark
Exercise to Improve Brain Health in Older African AmericansPhase 2Newark
A Postmarketing Study of LEQEMBI in South Korean Participants With Alzheimer's Disease—Nutley
A Postmarketing Study of Lecanemab for the Treatment of Participants With Alzheimer's Disease—Nutley
A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)Phase 3Princeton
A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2)Phase 3Ridgewood
Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease StudiesPhase 3Ridgewood
A Study of Donanemab (LY3002813) in Participants Who Completed Study AACM (TRAILBLAZER-ALZ 3-EXT).Phase 3Springfield
A Study to Investigate the Safety and Effectiveness of SAR448851 in Participants With Early Alzheimer's DiseasePhase 2Springfield
A First-In-Human Study of LY3954068 in Participants With Early Symptomatic Alzheimer's DiseasePhase 1Toms River
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's DiseasePhase 3Toms River
A Study to Assess the Efficacy and Safety of ITI-1284 in the Treatment of Agitation Associated With Alzheimer's DementiaPhase 2Toms River
A Study to Assess the Efficacy and Safety of ITI-1284 in the Treatment of Psychosis Associated With Alzheimer's DiseasePhase 2Toms River
A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)Phase 3Toms River
A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's DiseasePhase 3Toms River
Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)Phase 3Toms River
Open-label Extension Study in Participants With Early Alzheimer's DiseasePhase 2Toms River
Study of LHP588 in Subjects With P. Gingivalis-Positive Alzheimer's DiseasePhase 2Toms River
A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Alzheimer's Disease PsychosisPhase 2West Long Branch

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.